Zydus Lifesciences Announcements
Zydus launches biosimilar Denosumab 120 mg SC - protecting bone health in cancer patients.
10 Dec, 2025 | 10:18am • Source: BSE
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 10, 2025, titled "Zydus launches biosimilar Denosumab 120 mg SC protecting bone...
10 Dec, 2025 | 10:16am • Source: NSE
Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab), in US and Canada.
09 Dec, 2025 | 05:31pm • Source: BSE
Zydus receives EIR for the injectable facility located at Jarod.
04 Dec, 2025 | 12:47pm • Source: BSE
Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg.
27 Nov, 2025 | 04:31pm • Source: BSE
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 26, 2025, titled "Zydus and RK Pharma enter into an exclusive licensing...
26 Nov, 2025 | 12:44pm • Source: NSE
Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market.
26 Nov, 2025 | 12:27pm • Source: BSE
Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg, and 240 mg.
25 Nov, 2025 | 03:58pm • Source: BSE
Corporate presentation
25 Nov, 2025 | 11:19am • Source: BSE
Newspaper publication of notice of loss of share certificate of the Company published in the Financial Express English and Gujarati editions, both on November 18,...
18 Nov, 2025 | 12:10pm • Source: BSE
Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015
17 Nov, 2025 | 07:07pm • Source: BSE
Newspaper publication of notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on November 14,...
14 Nov, 2025 | 01:57pm • Source: BSE
Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial.
14 Nov, 2025 | 01:45pm • Source: BSE
Copy of newspaper publication
12 Nov, 2025 | 04:07pm • Source: BSE
Notice of Postal Ballot
11 Nov, 2025 | 11:15am • Source: BSE
Zydus receives approval from China''s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg.
11 Nov, 2025 | 09:56am • Source: BSE
Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg.
07 Nov, 2025 | 06:01pm • Source: BSE
Copy of newspaper cutting with regard to publication of unaudited financial results for the quarter / half year ended on September 30, 2025, in Financial...
07 Nov, 2025 | 11:42am • Source: BSE
Audio link
06 Nov, 2025 | 06:56pm • Source: BSE